Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ALK-001

Phase 3Small molecule

AAlkeus Pharmaceuticals, Inc.

1

Indications

5

Total Trials

3

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stargardt DiseaseEnrolling by invitation

Stargardt DiseasePhase 3

Enrolling by invitation

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Stargardt Disease

NCT04239625

Q4 2030

Phase 3Recruiting

Stargardt Disease

NCT07419334

Clinical

Trials by Indication[1]

Stargardt Disease3 trials

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Active, not recruiting·AAlkeus Pharmaceuticals, Inc.·Phase 2·NCT04239625·200 enrolled

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Enrolling by invitation·AAlkeus Pharmaceuticals, Inc.·Phase 2·NCT02402660·160 enrolled

A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK 001) on the Progression of Stargardt Disease (STGD)

Recruiting·AAlkeus Pharmaceuticals, Inc.·Phase 3·NCT07419334·230 enrolled

Geographic Atrophy1 trial

Phase 2/3 Study of ALK-001 in Geographic Atrophy

Completed·AAlkeus Pharmaceuticals, Inc.·Phase 2/3·NCT03845582·200 enrolled

Phase 11 trial

Phase 1 Safety Study of ALK-001 in Healthy Volunteers

Completed·AAlkeus Pharmaceuticals, Inc.·Phase 1·NCT02230228·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ALK-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALK-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALK-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alkeus Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAlkeus Pharmaceuticals, Inc.

Related News